We are live on ! Find out more
PACB icon

Pacific Biosciences

81 hedge funds and large institutions have $184M invested in Pacific Biosciences in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 18 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

199% more call options, than puts

Call options by funds: $454K | Put options by funds: $152K

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

147% more capital invested

Capital invested by funds: $74.4M → $184M (+$109M)

106% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 18

14% more funds holding

Funds holding: 7181 (+10)

Holders
81
Holders Change
+10
Holders Change %
+14.08%
% of All Funds
2.63%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
37
Reduced
18
Closed
6
Calls
$454K
Puts
$152K
Net Calls
+$302K
Net Calls Change
+$267K
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
51
Catapult Capital Management
New York
$276K +$174K +50,000 New
DTL
52
Dynamic Technology Lab
Singapore
$275K +$129K +37,212 +300%
MLICM
53
Metropolitan Life Insurance Company (MetLife)
New York
$235K +$148K +42,556 New
JP Morgan Chase
54
JP Morgan Chase
New York
$216K +$98.1K +28,255 +260%
BRWA
55
B. Riley Wealth Advisors
Florida
$197K +$124K +35,626 New
DekaBank Deutsche Girozentrale
56
DekaBank Deutsche Girozentrale
Germany
$187K +$117K +33,800 New
Verition Fund Management
57
Verition Fund Management
Connecticut
$180K -$78.7K -22,676 -41%
FNBT
58
FineMark National Bank & Trust
Florida
$166K +$104K +30,000 New
AIG
59
American International Group
New York
$165K +$15.1K +4,351 +17%
Two Sigma Investments
60
Two Sigma Investments
New York
$165K +$10.3K +2,954 +11%
BA
61
Boston Advisors
Massachusetts
$140K +$87.9K +25,324 New
VKH
62
Virtu KCG Holdings
New York
$135K +$84.8K +24,439 New
Ameriprise
63
Ameriprise
Minnesota
$134K +$666 +192 +0.8%
LMF
64
LMR Master Fund
Cayman Islands
$126K +$79.2K +22,809 New
Citigroup
65
Citigroup
New York
$119K +$5.69K +1,640 +8%
VAM
66
Visium Asset Management
New York
$111K -$3.45M -994,000 -98%
Bank of America
67
Bank of America
North Carolina
$96K +$26.1K +7,510 +76%
Group One Trading
68
Group One Trading
Illinois
$87K +$28.9K +8,318 +112%
BG
69
BlackRock Group
United Kingdom
$75K +$46.9K +13,520 New
AQR Capital Management
70
AQR Capital Management
Connecticut
$71K +$44.8K +12,900 New
AG
71
Aperio Group
California
$67K +$41.9K +12,081 New
HK
72
Horizon Kinetics
New York
$66K
TRCT
73
Tower Research Capital (TRC)
New York
$62K +$32.2K +9,287 +464%
Goldman Sachs
74
Goldman Sachs
New York
$61K +$38.1K +10,972 New
WA
75
WFG Advisors
Texas
$38K -$2.78K -800 -10%

PACB Hedge Fund Activity: Q3 2013 in Review

81 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2013, worth a combined $184M — up 147% from $74.4M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new PACB positions and 6 closed out — a net gain of 11 holders — while 37 added to existing stakes and 18 trimmed.

The largest buyer was Maverick Capital, adding an estimated $7.92M. The largest seller was Visium Asset Management, cutting an estimated $3.45M.

  • 81 institutional investors held Pacific Biosciences (PACB) as of Q3 2013, up from 71 in Q2 2013.
  • Funds reported $184M of Pacific Biosciences stock for Q3 2013, up 147% quarter-over-quarter.
  • 17 funds opened new Pacific Biosciences positions in Q3 2013 and 6 closed out, a net change of +11 holders.
  • The largest Pacific Biosciences buyer in Q3 2013 was Maverick Capital, an estimated $7.92M added.
  • The largest Pacific Biosciences seller in Q3 2013 was Visium Asset Management, an estimated $3.45M sold.

Based on aggregated 13F filings for Q3 2013.